Neocortical neuronal, synaptic, and glial loss in multiple sclerosis
Abstract
Background: Recent pathologic investigations have shown that neocortical lesions are frequent in multiple sclerosis (MS). Structural MRI has shown that neocortical atrophy occurs early and can be substantial, but the specific substrate for this atrophy has not been defined quantitatively.
Objective: To investigate cortical thickness as well as neuronal, glial, and synaptic densities in MS.
Methods: We studied brain samples from 22 patients with MS and 17 control subjects. Neocortical lesions and cortical thickness were assessed on sections stained for myelin basic protein. Neuronal, glial, and synaptic densities were measured in type I leukocortical lesions, nonlesional neocortex, and non-MS control cortex. Immunoautoradiography was used to quantify synaptic densities.
Results: Neocortical lesions were common in patients with MS. Subpial type III (44%) and leukocortical type I (38%) lesions were more abundant than intracortical type II (18%) lesions. An overall relative neocortical thinning of 10% (p = 0.016) was estimated for the patients. Within the type I lesions, we found evidence for substantial cell (glial, 36%, p = 0.001; neuronal, 10%, p = 0.032) and synaptic (47% decrease in synaptophysin, p = 0.001) loss. Nonlesional neocortex did not show significant relative changes in neuronal, glial, or synaptic density.
Conclusions: Neocortical neuronal and glial degeneration is significant in multiple sclerosis. Synaptic loss was particularly striking in the neocortical lesions, which should make a major independent contribution to the expression of pathology. New therapies should be directed toward limiting this damage.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis: I. Frequency, patterns, and prediction. Neurology 1991;41:685–691.
2.
Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389–400.
3.
Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003;62:723–732.
4.
Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain 1999;122:17–26.
5.
Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol 2002;52:650–653.
6.
De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003;60:1157–1162.
7.
Chard DT, Griffin CM, Parker GJM, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing–remitting multiple sclerosis. Brain 2002;125:327–337.
8.
Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996;119:2009–2019.
9.
Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412–1420.
10.
Chen JT, Narayanan S, Collins DL, Smith SM, Matthews PM, Arnold DL. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage 2004;23:1168–1175.
11.
Bo L, Vedeler CA, Nyland H, Trapp BD, Mork SJ. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler 2003;9:323–331.
12.
Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL, Martin LJ. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 1997;56:933–944.
13.
Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572–580.
14.
Eastwood SL, Burnet PW, McDonald B, Clinton J, Harrison PJ. Synaptophysin gene expression in human brain: a quantitative in situ hybridization and immunocytochemical study. Neuroscience 1994;59:881–892.
15.
Masliah E, Terry R. The role of synaptic proteins in the pathogenesis of disorders of the central nervous system. Brain Pathol 1993;3:77–85.
16.
Schmitt AB, Breuer S, Polat L, et al. Retrograde reactions of Clarke’s nucleus neurons after human spinal cord injury. Ann Neurol 2003;54:534–539.
17.
Benowitz LI, Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci 1997;20:84–91.
18.
Bogdanovic N, Davidsson P, Volkmann I, Winblad B, Blennow K. Growth-associated protein GAP-43 in the frontal cortex and in the hippocampus in Alzheimer’s disease: an immunohistochemical and quantitative study. J Neural Transm 2000;107:463–478.
19.
Chance SA, Tzotzoli PM, Vitelli A, Esiri MM, Crow TJ. The cytoarchitecture of sulcal folding in Heschl’s sulcus and the temporal cortex in the normal brain and schizophrenia: lamina thickness and cell density. Neurosci Lett 2004;367:384–388.
20.
Abercrombie M. Estimation of nuclear population from microtome sections. Anat Rec 1946;94:239–247.
21.
Law AJ, Harrison PJ. The distribution and morphology of prefrontal cortex pyramidal neurons identified using anti-neurofilament antibodies SMI32, N200 and FNP7. Normative data and a comparison in subjects with schizophrenia, bipolar disorder or major depression. J Psychiatr Res 2003;37:487–499.
22.
Giehl KM, Tetzlaff W. BDNF and NT-3, but not NGF, prevent axotomy-induced death of rat corticospinal neurons in vivo. Eur J Neurosci 1996;8:1167–1175.
23.
Bonatz H, Rohrig S, Mestres P, Meyer M, Giehl KM. An axotomy model for the induction of death of rat and mouse corticospinal neurons in vivo. J Neurosci Methods 2000;100:105–115.
24.
Minagar A, Shapshak P, Fujimura R, Ownby R, Heyes M, Eisdorfer C. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 2002;202:13–23.
25.
Medana I, Martinic MA, Wekerle H, Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001;159:809–815.
26.
Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002;1:232–241.
27.
Wolswijk G. Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain 2000;123:105–115.
28.
Parry AM, Scott RB, Palace J, Smith S, Matthews PM. Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine. Brain 2003;126:2750–2760.
29.
Lund J, Lund R, Hendrickson A, Bunt A, Fuchs A. The origin of efferent pathways from the primary visual cortex, area 17, of the macaque monkey as shown by retrograde transport of horseradish peroxidase. J Comp Neurol 1975;164:287–303.
30.
Selkoe DJ. Alzheimer’s disease is a synaptic failure. Science 2002;298:789–791.
31.
Sarchielli P, Presciutti O, Tarducci R, et al. Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis. J Neurol 2002;249:902–910.
32.
Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125:2342–2352.
33.
Kapeller P, McLean MA, Griffin CM, et al. Preliminary evidence for neuronal damage in cortical grey matter and normal-appearing white matter in short duration relapsing–remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol 2001;248:131–138.
34.
Barkhof F. N-Acetyl-aspartate—a neuronal marker? Ann Neurol 2001;49:423–424.
35.
Clark J. N-Acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci 1998;20:271–276.
36.
De Stefano N, Matthews PM, Narayanan S, Francis GS, Antel JP, Arnold DL. Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient. Neurology 1997;49:1138–1141.
37.
Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001;248:979–986.
38.
Sailer M, Fischl B, Salat D, et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 2003;126:1734–1744.
39.
Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385–391.
40.
Rashid W, Parkes LM, Ingle GT, et al. Abnormalities of cerebral perfusion in multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:1288–1293.
41.
Gilmore C, DeLuca G, Bo L, et al. Spinal cord atrophy in multiple sclerosis caused by white matter volume loss. Arch Neurol 2005;62:1859–1862.
Information & Authors
Information
Published In
Copyright
© 2006.
Publication History
Published online: September 25, 2006
Published in print: September 26, 2006
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Myelin Pathology in Alzheimer's Disease: Potential Therapeutic Opportunities, Aging and disease, 15, 2, (698), (2024).https://doi.org/10.14336/AD.2023.0628
- Syntaxin 1A gene polymorphism in multiple sclerosis: a case–control study, The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 60, 1, (2024).https://doi.org/10.1186/s41983-024-00811-1
- The contribution of tumor necrosis factor to multiple sclerosis: a possible role in progression independent of relapse?, Journal of Neuroinflammation, 21, 1, (2024).https://doi.org/10.1186/s12974-024-03193-6
- Brain atrophy assessment in multiple sclerosis: technical– and subject-related barriers for translation to real-world application in individual subjects, Expert Review of Neurotherapeutics, 24, 11, (1081-1096), (2024).https://doi.org/10.1080/14737175.2024.2398484
- Associations between cortical lesions, optic nerve damage, and disability at the onset of multiple sclerosis: insights into neurodegenerative processes., Multiple Sclerosis and Related Disorders, 83, (105413), (2024).https://doi.org/10.1016/j.msard.2023.105413
- Visual evoked potentials in multiple sclerosis: P100 latency and visual pathway damage including the lateral geniculate nucleus, Clinical Neurophysiology, 161, (122-132), (2024).https://doi.org/10.1016/j.clinph.2024.02.020
- Acute Disseminated Encephalomyelitis, Reference Module in Neuroscience and Biobehavioral Psychology, (2024).https://doi.org/10.1016/B978-0-323-95702-1.00032-4
- Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis, Annals of Neurology, 96, 1, (1-20), (2024).https://doi.org/10.1002/ana.26913
- CNS Ageing in Health and Neurodegenerative Disorders, Journal of Clinical Medicine, 12, 6, (2255), (2023).https://doi.org/10.3390/jcm12062255
- An Animal Model for Chronic Meningeal Inflammation and Inflammatory Demyelination of the Cerebral Cortex, International Journal of Molecular Sciences, 24, 18, (13893), (2023).https://doi.org/10.3390/ijms241813893
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.